Translational Research

OCIG’s translational research aims to fast-track development of innovation in the following areas

Early detection and prevention led by Kian Behbakht, MD, MBA.

Cells undergo many changes prior to and during cancer development. Some of these molecular changes may represent important biomarkers for the early detection and diagnosis of ovarian cancer or may be detected on imaging using enhanced techniques.

Disease progression and metastasis spearheaded by Benjamin Bitler, PhD and Zachary Levi Watson, PhD.

While ovarian cancer may begin in the ovaries, fallopian tubes or peritoneum, it often spreads to other parts of the body. Exploring the role of genes or other organ systems involved in cancer dissemination can help us find ways to prevent cancer progression and metastasis.

Investigation of the tumor immune microenvironment under the guidance of Nicole Marjon, MD, PhD.

Immune checkpoint inhibitors have emerged as a breakthrough in cancer care but have not shown significant improvements in patients with ovarian cancer. Elucidating immune evasion mechanisms and the roles of cells and their interactions within the tumor microenvironment helps us develop strategies to enhance the immune response against ovarian cancer.

Development of novel therapeutic interventions coordinated by Benjamin Bitler, PhD, Kian Behbakht, MD, MBA, Lindsay Brubaker, MD, Bradley Corr, MD, and Marisa Moroney, MD.

Understanding mechanisms that contribute to disease progression and therapy resistance allows us to identify novel targets that guide drug development or ways to increase the effectiveness of available drugs.